Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US firm invests $16m in Indian blood cord banking and stem cell R&D project

This article was originally published in Clinica

Executive Summary

US firm StemCyte (Arcadia, California and Taiwan) has invested $16m in a public and private umbilical cord blood bank to be based in the Indian city of Ahmedabad. It will be co-owned by India's Apollo Hospital group (Chennai) and Cadila Pharmaceuticals (Ahmedabad), which will hold 26% each. StemCyte will double its initial investment in StemCyte Therapeutics India following the project's implementation, which is expected to be in 9-12 months. The company, which specialises in researching the therapeutic use of umbilical cord blood (UCB) stem cells, plans to use the centre in India to study the use of UCB stem cells to treat non-haematological conditions such as diabetes, stoke and liver disease.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046340

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel